CO6551683A2 - Tratamiento para trastornos gastrointestinales - Google Patents

Tratamiento para trastornos gastrointestinales

Info

Publication number
CO6551683A2
CO6551683A2 CO12081055A CO12081055A CO6551683A2 CO 6551683 A2 CO6551683 A2 CO 6551683A2 CO 12081055 A CO12081055 A CO 12081055A CO 12081055 A CO12081055 A CO 12081055A CO 6551683 A2 CO6551683 A2 CO 6551683A2
Authority
CO
Colombia
Prior art keywords
gastrointestinal disorders
treatment
present
pharmaceutical compositions
provides
Prior art date
Application number
CO12081055A
Other languages
English (en)
Spanish (es)
Inventor
Mark Currie
Angelika Fretzen
Daniel P Zimmer
Marco Kessler
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6551683(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of CO6551683A2 publication Critical patent/CO6551683A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
CO12081055A 2009-11-09 2012-05-16 Tratamiento para trastornos gastrointestinales CO6551683A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
CO6551683A2 true CO6551683A2 (es) 2012-10-31

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12081055A CO6551683A2 (es) 2009-11-09 2012-05-16 Tratamiento para trastornos gastrointestinales

Country Status (26)

Country Link
US (3) US20140179607A9 (cg-RX-API-DMAC7.html)
EP (1) EP2499154B1 (cg-RX-API-DMAC7.html)
JP (1) JP5913115B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120115495A (cg-RX-API-DMAC7.html)
CN (1) CN102812038B (cg-RX-API-DMAC7.html)
AR (1) AR078950A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010314866B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012011730A2 (cg-RX-API-DMAC7.html)
CA (1) CA2779482A1 (cg-RX-API-DMAC7.html)
CL (1) CL2012001186A1 (cg-RX-API-DMAC7.html)
CO (1) CO6551683A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120303A (cg-RX-API-DMAC7.html)
EA (1) EA022817B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011962A (cg-RX-API-DMAC7.html)
ES (1) ES2620153T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20166435B (cg-RX-API-DMAC7.html)
IL (1) IL219596A0 (cg-RX-API-DMAC7.html)
MX (2) MX350046B (cg-RX-API-DMAC7.html)
NZ (1) NZ599751A (cg-RX-API-DMAC7.html)
PH (1) PH12012500916B1 (cg-RX-API-DMAC7.html)
SG (1) SG10201407403UA (cg-RX-API-DMAC7.html)
TW (1) TWI482626B (cg-RX-API-DMAC7.html)
UA (1) UA114274C2 (cg-RX-API-DMAC7.html)
UY (2) UY33018A (cg-RX-API-DMAC7.html)
WO (1) WO2011057272A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201203342B (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8034782B2 (en) 2008-07-16 2011-10-11 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2012510518A (ja) * 2008-12-02 2012-05-10 アイロンウッド ファーマシューティカルズ,インコーポレーテッド 体液貯留障害を処置するための方法および組成物
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
CA2835624A1 (en) * 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
WO2012170804A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
MX347354B (es) * 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
JP2016521249A (ja) * 2012-07-12 2016-07-21 フォレスト ラボラトリーズ ホールディングス リミテッド リナクロチド組成物
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス,インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
US20160235807A1 (en) * 2013-10-09 2016-08-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
WO2016015055A1 (en) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Colon cleansing compositions
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
DE69433564T2 (de) 1993-10-26 2004-12-23 Thomas Jefferson University Verbindungen, die kolorektale Krebszellen spezifisch binden, und Verfahren zu ihrer Verwendung
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO2001080871A2 (de) * 2000-04-22 2001-11-01 Ipf Pharmaceuticals Gmbh Anwendung von guanylat-zyklase-c (gc-c) agonisten als insulinotrope faktoren zur behandlung von diabetes mellitus typ 2
DK1594517T3 (da) 2003-01-28 2007-10-29 Microbia Inc Sammensætninger til behandlingen af gastrointestinale lidelser
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CA2619650A1 (en) 2005-08-19 2007-02-22 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2559319T3 (es) * 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
SG193801A1 (en) 2008-08-15 2013-10-30 Ironwood Pharmaceuticals Inc Linaclotide-containing formulations for oral administration
US20120039949A1 (en) 2008-09-04 2012-02-16 Ironwood Pharmaceuticals, Inc. Stable Solid Formulations of GC-C Receptor Agonist Polypeptides Suitable for Oral Administration
GEP20166435B (en) * 2009-11-09 2016-02-25 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
US8748575B2 (en) 2010-06-09 2014-06-10 Combimab, Inc. Therapeutic peptides

Also Published As

Publication number Publication date
CA2779482A1 (en) 2011-05-12
AR078950A1 (es) 2011-12-14
TWI482626B (zh) 2015-05-01
IL219596A0 (en) 2012-06-28
SG10201407403UA (en) 2014-12-30
PH12012500916B1 (en) 2018-03-23
AU2010314866A1 (en) 2012-05-31
JP2013510182A (ja) 2013-03-21
KR20120115495A (ko) 2012-10-18
UY33017A (es) 2011-06-30
WO2011057272A1 (en) 2011-05-12
EA201290322A1 (ru) 2013-01-30
US20130085107A1 (en) 2013-04-04
MX350046B (es) 2017-08-24
EP2499154A1 (en) 2012-09-19
ES2620153T3 (es) 2017-06-27
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
CL2012001186A1 (es) 2013-07-12
MX2012005368A (es) 2012-06-13
UA114274C2 (uk) 2017-05-25
CN102812038A (zh) 2012-12-05
US8946158B2 (en) 2015-02-03
EA022817B1 (ru) 2016-03-31
US20140024593A1 (en) 2014-01-23
BR112012011730A2 (pt) 2016-03-08
JP5913115B2 (ja) 2016-05-11
TW201116291A (en) 2011-05-16
NZ599751A (en) 2014-08-29
US8507447B2 (en) 2013-08-13
GEP20166435B (en) 2016-02-25
ECSP12011962A (es) 2012-07-31
UY33018A (es) 2011-01-31
ZA201203342B (en) 2013-01-30
CR20120303A (es) 2012-08-08
EP2499154B1 (en) 2016-12-21
PH12012500916A1 (en) 2018-01-29
AU2010314866B2 (en) 2014-10-30
US20140179607A9 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
CO6551683A2 (es) Tratamiento para trastornos gastrointestinales
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
EA201591166A1 (ru) Ингибиторы аутотаксина
PH12013502261A1 (en) Partially saturated tricyclic compounds and methods of making and using same
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX349796B (es) Composiciones farmacéuticas para usarse en el tratamiento de trastornos oncológicos mediante el uso de coenzima q10.
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX376008B (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
EA201691079A1 (ru) Комбинированная терапия для лечения онкологического заболевания
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
RU2018145985A (ru) Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX2014008705A (es) Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos.
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
MX2015005732A (es) Compuestos tricíclicos y métodos para hacer y utilizar los mismos.

Legal Events

Date Code Title Description
FG Application granted